Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, June 5, 2017
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting
Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab
Thursday, June 1, 2017
Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities
Wednesday, May 31, 2017
Eisai Enters Into a New Joint Research Agreement With the Broad Institute to Develop an Antimalarial Medicine
Thursday, May 18, 2017
Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting
Wednesday, April 19, 2017
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis
Tuesday, April 11, 2017
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series
Wednesday, April 5, 2017
Eisai and Meiji Enter Into Licensing Agreement Concerning Parkinson's Disease Drug Safinamide in Japan and Asia
Eisai Presents Data of Mechanisms of Action Relating to Tumor Immune Response Regarding Combination of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody at AACR 108th Annual Meeting
Tuesday, April 4, 2017
Eisai to Launch Smell Identification Test UPSIT Series in Japan

Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: